Crizotinib Dosage

Generic name: crizotinib
Brand name: Xalkori
Dosage form: oral capsule
Drug class: Multikinase inhibitors

Medically reviewed by  A Ras MD.

 

Recommended Adult Dosing

Dosage forms:  CAP: 200 mg, 250 mg

ALK- or ROS1-positive non-small cell lung CA, metastatic

[250 mg PO bid]

Info: do not open cap

ALK-positive inflammatory myofibroblastic tumor, unresectable, recurrent or refractory

[250 mg PO bid]

Info: do not open cap

ALK-positive systemic anaplastic large cell lymphoma, relapsed or refractory

[BSA 0.6-0.8 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 200 mg PO bid); Info: for young adult pts; do not open cap

[BSA 0.81-1.16 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 250 mg PO bid); Info: for young adult pts; do not open cap

[BSA 1.17-1.51 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 400 mg PO bid); Info: for young adult pts; do not open cap

[BSA 1.52-1.69 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 450 mg PO bid); Info: for young adult pts; do not open cap

[BSA >1.69 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 500 mg PO bid); Info: for young adult pts; do not open cap

Renal dosing

[non-small cell lung CA or inflammatory myofibroblastic tumor]

CrCl <30: 250 mg qd

HD/PD: not defined

[anaplastic large cell lymphoma, BSA 0.6-0.8 m^2]

CrCl <30: avoid use

HD/PD: not defined

[anaplastic large cell lymphoma, BSA 0.81-1.16 m^2]

CrCl <30: 250 mg qd

HD/PD: not defined

[anaplastic large cell lymphoma, BSA 1.17-1.69 m^2]

CrCl <30: 200 mg bid

HD/PD: not defined

[anaplastic large cell lymphoma, BSA >1.69 m^2]

CrCl <30: 250 mg bid

HD/PD: not defined

Hepatic dosing

[non-small cell lung CA or inflammatory myofibroblastic tumor]

bilirubin 1.6-3x ULN and any AST: 200 mg bid; bilirubin >3x ULN and any AST: 250 mg qd

[anaplastic large cell lymphoma, BSA 0.6-0.8 m^2]

bilirubin 1.6-3x ULN and any AST: 250 mg qd; bilirubin >3x ULN and any AST: avoid use

[anaplastic large cell lymphoma, BSA 0.81-1.16 m^2]

bilirubin 1.6-3x ULN and any AST: 200 mg bid; bilirubin >3x ULN and any AST: 250 mg qd

[anaplastic large cell lymphoma, BSA 1.17-1.69 m^2]

bilirubin 1.6-3x ULN and any AST: 250 mg bid; bilirubin >3x ULN and any AST: 200 mg bid

[anaplastic large cell lymphoma, BSA >1.69 m^2]

bilirubin 1.6-3x ULN and any AST: 400 mg bid; bilirubin >3x ULN and any AST: 250 mg bid

 Recommended Peds Dosing

Dosage forms:  CAP: 200 mg, 250 mg

ALK-positive inflammatory myofibroblastic tumor, unresectable, recurrent or refractory

[1 yo and older, BSA 0.6-0.8 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 200 mg PO bid); Info: do not open cap

[1 yo and older, BSA 0.81-1.16 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 250 mg PO bid); Info: do not open cap

[1 yo and older, BSA 1.17-1.51 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 400 mg PO bid); Info: do not open cap

[1 yo and older, BSA 1.52-1.69 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 450 mg PO bid); Info: do not open cap

[1 yo and older, BSA >1.69 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 500 mg PO bid); Info: do not open cap

ALK-positive systemic anaplastic large cell lymphoma, relapsed or refractory

[1 yo and older, BSA 0.6-0.8 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 200 mg PO bid); Info: do not open cap

[1 yo and older, BSA 0.81-1.16 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 250 mg PO bid); Info: do not open cap

[1 yo and older, BSA 1.17-1.51 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 400 mg PO bid); Info: do not open cap

[1 yo and older, BSA 1.52-1.69 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 450 mg PO bid); Info: do not open cap

[1 yo and older, BSA >1.69 m^2]

Dose: 280 mg/m^2/dose PO bid (round to 500 mg PO bid); Info: do not open cap

Renal dosing

[BSA 0.6-0.8 m^2]

CrCl <30: avoid use

HD/PD: not defined

[BSA 0.81-1.16 m^2]

CrCl <30: 250 mg qd

HD/PD: not defined

[BSA 1.17-1.69 m^2]

CrCl <30: 200 mg bid

HD/PD: not defined

[BSA >1.69 m^2]

CrCl <30: 250 mg bid

HD/PD: not defined

Hepatic dosing

[BSA 0.6-0.8 m^2]

bilirubin 1.6-3x ULN and any AST: 250 mg qd; bilirubin >3x ULN and any AST: avoid use

[BSA 0.81-1.16 m^2]

bilirubin 1.6-3x ULN and any AST: 200 mg bid; bilirubin >3x ULN and any AST: 250 mg qd

[BSA 1.17-1.69 m^2]

bilirubin 1.6-3x ULN and any AST: 250 mg bid; bilirubin >3x ULN and any AST: 200 mg bid

[BSA >1.69 m^2]

bilirubin 1.6-3x ULN and any AST: 400 mg bid; bilirubin >3x ULN and any AST: 250 mg bid

 

SRC: NLM .